Pfizer secures exclusive option to acquire gene therapy company vivet therapeutics

by Ysios Capital

Vivet is supported by international life science investors including Novartis Venture Fund, Roche Venture Fund, HealthCap, Columbus Venture Partners, Ysios Capital, Kurma Partners and Idinvest Partner...

Read more

Minoryx Therapeutics raises €21.3M in Series B funding round

by Ysios Capital

The funding round was led by Fund+, joined by SFPI-FPIM, S.R.I.W. and Sambrinvest, in addition to all Series A investors (Ysios Capital, Kurma Partners, Roche Venture Fund, Idinvest Partners, Chiesi V...

Read more

Ysios Capital strengthens its team with the appointment of Guillem Laporta as Principal and two new Venture Partners

by Ysios Capital

Ysios Capital, a leading biotechnology venture capital firm in Spain, has announced that it has appointed Guillem Laporta as Principal and two new Venture Partners: Lance Berman and Claudia D’August...

Read more

Lundbeck to acquire Prexton Therapeutics, participated by Ysios Capital, in a deal valued at up to €905 million

by Ysios Capital

H. Lundbeck A/S (Lundbeck) and Prexton Therapeutics BV (Prexton) have announced the signing of a definitive agreement in which Lundbeck will acquire Prexton. Under terms of the agreement, Lundbeck wil...

Read more

QIAGEN enters into agreement to acquire STAT-Dx, plans to launch a next-generation, fully integrated multiplex platform for syndromic disease testing

by Ysios Capital

QIAGEN N.V. has announced it has entered into an agreement to acquire STAT-Dx, a privately-held company developing the next generation of multiplex diagnostics for one-step, fully integrated molecular...

Read more

Xeltis Closes €45 Million in Oversubscribed Series C Financing to Advance Aortic and Pulmonary Valve Programs. Ysios Capital participates in the round

by Ysios Capital

The funding round was led by a global strategic investor with participation from venture capital fund Ysios Capital and a number of large private investors. Existing institutional investors (LSP, Kurm...

Read more

Ysios Capital invierte € 2,2 millones en Babyscripts, de EE.UU

by Ysios Capital

La inversión de Ysios se enmarca en la segunda ronda de financiación de Babyscripts, en la que ha captado 5,5 millones de dólares en total. Así, 2,5 millones han sido aportados por Ysios y el rest...

Read more

Anaconda Biomed Secures 15 Million Euro in Series A Financing Led by Ysios Capital, Innogest Capital and Omega Funds

by Ysios Capital

Anaconda Biomed Secures 15 Million Euro in Series A Financing Led by Ysios Capital, Innogest Capital and Omega Funds

Read more

BioClin Therapeutics, Inc., Raises $30 Million in Series B Financing Led by Sofinnova Ventures and Ysios Capital

by Ysios Capital

BioClin Therapeutics, Inc., a privately-­‐held clinical stage drug development company developing a first-­‐in-­‐class anti-­‐FGFR3 (fibroblast growth factor receptor 3) monoclonal antibod...

Read more

Prexton Therapeutics - participated by Ysios Capital - Series B financing round raises € 29 millions to advance its novel Parkinson’s therapeutic

by Ysios Capital

Forbion Capital Partners (NL) and Seroba Life Sciences (IE) co-led the financing round, which includes current investors Merck Ventures (NL), Ysios Capital (ES) and Sunstone Capital (DK). Marco Boorsm...

Read more

TiGenix, participated by Ysios Capital, announces launch of proposed initial public offering in the United States

by Ysios Capital

TiGenix has announced that it intends to offer and sell, subject to market and other conditions, 2.75 million American Depositary Shares representing 55 million ordinary shares in an initial public o...

Read more
Subscribe to Directory
Write an Article

Highlight

3i closes second European CLO, Harvest V...

by 3i Group

3i Group plc (“3i” or “3i Group”), an international investor, ...

La restauración, sector de moda para lo...

by Albia Capital Partners

36.763 millones de euros, son las ventas que alcanzó en 2018 el secto...

Photos Stream